Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors

"The most valuable advantage we see so far would be the safety profile associated with HER2-TAC T-cells and it is very well differentiated thus far compared to approved CARs. So far we have not seen any dose limiting toxicities, cytokine release syndrome, or neurotoxicity in dose levels 1 and 2."

Triumvira Immunologics’ TAC01-HER2, a HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, was well-tolerated with early signs of clinical activity. In new data from cohort 2 of the phase 1/2 TACTIC-2 study, the therapy yielded a partial response in a patient with stage 4b gastric cancer and a 75% disease control rate.

Data from the study were presented by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute, at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France. The trial will be enrolling in its phase 2 portion in the beginning of 2023.

CGTLive spoke with senior author Deyaa Adib, MD, chief medical officer, Triumvira Immunologics, to learn more about unmet needs in patients with solid tumors. He discussed the advantages of the TAC T-cell technology in addressing these unmet needs, including a positive safety profile with lower rates of cytokine release syndrome compared to those seen in other cell therapy trials.

Click here to read more coverage of ESMO Congress 2022.

REFERENCE

Schlechter BL, Ileana Dumbrava EE, Olson D, et al. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Presented at: ESMO Congress 2022, September 9-13, Paris, France. Poster #778TiP